
CBI member Pfizer recently released its results for the first quarter of 2012, reporting revenues from its Emerging Markets unit up 9% operationally in comparison to a year earlier. The strong performance was primarily due to continued volume growth across the product portfolio, particularly in China, Russia, and Mexico, as a result of more focused, targeted promotional efforts for key products. Read more here.